Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Evofem Biosciences, Inc. (EVFM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Evofem Biosciences Announces Financial Results for the Second Quarter of 2023"
06/16/2023 8-K Quarterly results
Docs: "Evofem Biosciences Announces Financial Results for the First Quarter of 2023"
04/28/2023 8-K Quarterly results
Docs: "EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEET DATA December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 2,769 $ 7,732 Restricted cash 1,207 5,056 Trade accounts receivable, net 1,126 6,449 Inventories 5,379 7,674 Prepaid and other current assets 2,218 3,229 Total current assets 12,699 30,140 Property and equipment, net 3,940 5,774 Operating lease right-of-use assets 4,406 5,395 Other noncurrent assets 4,118 1,203 Total assets $ 25,163 $ 42,512 Liabilities, convertible and redeemable preferred stock and stockholders’ deficit Current liabilities: Accounts payable $ 14,984 $ 10,316 Convertible notes payable - carried at fair value 39,416 81,717 Convertible notes payable - Adjuvant 26,268 27,209 Accrued expenses 4,124 8,370 Accrued compens..."
05/04/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "Evofem Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
08/11/2021 8-K Quarterly results
Docs: "Evofem Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Update"
05/06/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Evofem Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update Launched Phexxi™ in U.S. for Hormone-free Contraception Initiated Pivotal Phase 3 EVOGUARD Trial of EVO100 for Prevention of Chlamydia and Gonorrhea Secured $25 Million Strategic Investment from Adjuvant Capital Management to Host Conference Call Monday, November 9, 2020 at 5:00 p.m. ET"
08/04/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
Docs: "Evofem Biosciences Reports First Quarter 2020 Financial Results and Provides Corporate Update - On-Track for Phexxi™ PDUFA Date: May 25, 2020 - - End-of-Phase 2 Meeting with FDA Today to Review Results of the AMPREVENCE Trial - - Management to Host Conference Call Wednesday, May 6, 2020 at 11:00 a.m. EDT -"
11/06/2019 8-K Quarterly results
Docs: "Evofem Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update Company on Track for Amphora NDA Resubmission to the U.S. FDA Phase 2b AMPREVENCE Trial Results Anticipated in Q4 2019 Management to Host Conference Call Thursday, November 7, 2019 at 11:00 a.m. EST"
08/05/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "Evofem Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update Management to Host Conference Call at 11:00 a.m. EDT"
11/07/2018 8-K Quarterly results
Docs: "Evofem Biosciences Reports Third Quarter 2018 Financial Results and Provides Corporate Update Management to Host Conference Call at 11:00 a.m. EST"
08/02/2018 8-K Quarterly results
Docs: "Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data now expected in Late 2018 Management to Host Conference Call at 11:00 a.m. ET"
11/08/2017 8-K Quarterly results
Docs: "NEOTHETICS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS"
08/10/2017 8-K Quarterly results
Docs: "NEOTHETICS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS"
05/11/2017 8-K Form 8-K - Current report
03/23/2017 8-K Quarterly results
Docs: "NEOTHETICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER 2016 FINANCIAL RESULTS"
11/10/2016 8-K Form 8-K - Current report
08/11/2016 8-K Form 8-K - Current report
05/12/2016 8-K Form 8-K - Current report
03/29/2016 8-K Form 8-K - Current report
11/12/2015 8-K Form 8-K - Current report
08/13/2015 8-K Form 8-K - Current report
05/14/2015 8-K Form 8-K - Current report
03/26/2015 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy